Prognostic biomarkers of survival in oropharyngeal squamous cell carcinoma: Systematic review and meta-analysis

Head and Neck

Volumn 35, Issue 7, 2013, Pages 1048-1055

  Rainsbury, James W ^a   Ahmed, Waseem ^a   Williams, Hazel K ^b   Roberts, Sally ^a   Paleri, Vinidh ^c   Mehanna, Hisham ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

biomarker; human papillomavirus; oropharyngeal cancer; prognostic; survival

Indexed keywords

BIOLOGICAL MARKER; CD3 ANTIGEN; CD31 ANTIGEN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; FRAGILE HISTIDINE TRIAD PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMD PROTEIN; KI 67 ANTIGEN; LUNG RESISTANCE PROTEIN; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; POLO LIKE KINASE; PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P16; PROTEIN P53; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SURVIVIN; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS DNA;

CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 16Q; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DISEASE SPECIFIC SURVIVAL; GENE AMPLIFICATION; GENE DELETION; GENE LOSS; HUMAN; IN SITU HYBRIDIZATION; LONGITUDINAL STUDY; LOSS OF FUNCTION MUTATION; META ANALYSIS; OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; HUMANS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84879421626     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.22950     Document Type: Conference Paper

References (58)

1. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
2. Ragin CC, Taioli E,. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007; 121: 1813-1820.
3. National Cancer Intelligence Network [Internet]. London. 2010. Available from http://www.ncin.org.uk/
4. Survaillance Epidemiology and End Results [Internet]. United States National Cancer Institute; 2009. Available from http://seer.cancer.gov/5.
5. Nasman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009; 125: 362-366.
6. Aebersold DM, Froehlich SC, Jonczy M, et al. Expression of transforming growth factor-alpha, epidermal growth factor receptor and platelet-derived growth factors A and B in oropharyngeal cancers treated by curative radiation therapy. Radiother Oncol 2002; 63: 275-283.
7. Psyrri A, Yu Z, Weinberger PM, et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 2005; 11: 5856-5862.
8. Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001; 61: 2911-2916.
9. Aebersold DM, Kollar A, Beer KT, Laissue J, Greiner RH, Djonov V,. Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation. Int J Cancer 2001; 96: 41-54.
10. De Petrini M, Ritta M, Schena M, et al. Head and neck squamous cell carcinoma: role of the human papillomavirus in tumour progression. New Microbiol 2006; 29: 25-33.
11. Grabenbauer GG, Muhlfriedel C, Rodel F, et al. Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify patients at high risk for local recurrence after surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 2000; 48: 1041-1050.
12. Fei JM, Hong A, Dobbins TA, et al. Prognostic significance of vascular endothelial growth factor in squamous cell carcinomas of the tonsil in relation to human papillomavirus status and epidermal growth factor receptor. Ann Surg Oncol 2009; 16: 2908-2917.
13. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 2001; 7: 3399-3403.
14. Winter SC, Shah KA, Han C, et al. The relation between hypoxia-inducible factor (HIF)-1 alpha and HIF-2 alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer 2006; 107: 757-766.
15. Gold KA, Kim ES,. Role of molecular markers and gene profiling in head and neck cancers. Curr Opin Oncol 2009; 21: 206-211.
16. Chang SS, Califano J,. Current status of biomarkers in head and neck cancer. J Surg Oncol 2008; 97: 640-643.
17. Hayden JA, Cote P, Bombardier C,. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006; 144: 427-437.
18. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM,. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005; 93: 387-391.
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
20. Klussmann JP, Gultekin E, Weissenborn SJ, et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 2003; 162: 747-753.
21. Mellin H, Friesland S, Lewensohn R, Dalianis T, Munck-Wikland E,. Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer 2000; 89: 300-304.
22. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006; 24: 736-747.
23. Awwad S, Jaros E, Somes J, Lunec J,. P53 overexpression in head and neck carcinoma and radiotherapy results. Int J Radiat Oncol Biol Phys 1996; 34: 323-332.
24. Chang BW, Kim DH, Kowalski DP, et al. Prognostic significance of cyclooxygenase-2 in oropharyngeal squamous cell carcinoma. Clin Cancer Res 2004; 10: 1678-1684.
25. Ernster JA, Sciotto CG, O'Brien MM, et al. Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus. Laryngoscope 2007; 117: 2115-2128.
26. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-269.
27. Fallai C, Perrone F, Licitra L, et al. Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV status. Int J Radiat Oncol Biol Phys 2009; 75: 1053-1059.
28. Hafkamp HC, Manni JJ, Haesvoets A, et al. Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer 2008; 122: 2656-2664.
29. Klozar J, Kratochvil V, Salakova M, et al. HPV status and regional metastasis in the prognosis of oral and oropharyngeal cancer. Eur Arch Otorhinolaryngol 2008; 265 (Suppl 1): S75-S82.
30. Klussmann JP, Mooren JJ, Lehnen M, et al. Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications. Clin Cancer Res 2009; 15: 1779-1786.
31. Knecht R, Oberhauser C, Strebhardt K,. PLK (polo-like kinase), a new prognostic marker for oropharyngeal carcinomas. Int J Cancer 2000; 89: 535-536.
32. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM,. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 2001; 92: 805-813.
33. Nichols AC, Faquin WC, Westra WH, et al. HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg 2009; 140: 228-234.
34. Otero-Garcia JE, Youssef E, Enamorado II, et al. Prognostic significance of p53 and FHIT in advanced oropharyngeal carcinoma. Am J Otolaryngol 2004; 25: 231-239.
35. Preuss SF, Weinell A, Molitor M, et al. Nuclear survivin expression is associated with HPV-independent carcinogenesis and is an indicator of poor prognosis in oropharyngeal cancer. Br J Cancer 2008; 98: 627-632.
36. Rajjoub S, Basha SR, Einhorn E, Cohen MC, Marvel DM, Sewell DA,. Prognostic significance of tumor-infiltrating lymphocytes in oropharyngeal cancer. Ear Nose Throat J 2007; 86: 506-511.
37. Silva P, West CM, Slevin N, et al. Tumor expression of major vault protein is an adverse prognostic factor for radiotherapy outcome in oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2007; 69: 133-140.
38. Yu Z, Weinberger PM, Sasaki C, et al. Phosphorylation of Akt (Ser473) predicts poor clinical outcome in oropharyngeal squamous cell cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 553-558.
39. Yu Z, Weinberger PM, Haffty BG, et al. Cyclin d1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma. Clin Cancer Res 2005; 11: 1160-1166.
40. Aebersold DM, Beer KT, Laissue J, et al. Intratumoral microvessel density predicts local treatment failure of radically irradiated squamous cell cancer of the oropharynx. Int J Radiat Oncol Biol Phys 2000; 48: 17-25.
41. Caminero MJ, Nunez F, Suarez C, Ablanedo P, Riera JR, Dominguez F,. Detection of p53 protein in oropharyngeal carcinoma. Prognostic implications. Arch Otolaryngol Head Neck Surg 1996; 122: 769-772.
42. Shi W, Kato H, Perez-Ordonez B, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 2009; 27: 6213-6221.
43. Li W, Thompson CH, O'Brien CJ, et al. Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int J Cancer 2003; 106: 553-558.
44. Sedaghat AR, Zhang Z, Begum S, et al. Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas. Laryngoscope 2009; 119: 1542-1549.
45. Ritta M, De Andrea M, Mondini M, et al. Cell cycle and viral and immunologic profiles of head and neck squamous cell carcinoma as predictable variables of tumor progression. Head Neck 2009; 31: 318-327.
46. Lindquist D, Romanitan M, Hammarstedt L, et al. Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7. Mol Oncol 2007; 1: 350-355.
47. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006; 24: 5630-5636.
48. Silva P, Slevin NJ, Sloan P, et al. Prognostic significance of tumor hypoxia inducible factor-1alpha expression for outcome after radiotherapy in oropharyngeal cancer. Int J Radiat Oncol Biol Phys 2008; 72: 1551-1559.
49. Andrews E,. Human papillomavirus associated oropharyngeal carcinomas in non-smokers and non-drinkers [dissertation]. Chapel Hill, NC: The University of North Carolina; 2007.
50. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008; 26: 3128-3137.
51. Lehnerdt GF, Franz P, Bankfalvi A, et al. The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma. Ann Oncol 2009; 20: 1094-1099.
52. Michaud WA, Nichols AC, Mroz EA, et al. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res 2009; 15: 1645-1654.
53. Levine AJ,. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
54. Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007; 25: 2164-2170.
55. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24: 4170-4176.
56. Hama T, Yuza Y, Saito Y, et al. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist 2009; 14: 900-908.
57. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
58. Young RJ, Rischin D, Fisher R, et al. Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2011; 20: 1230-1237.